Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 1387 |
| INN | None |
| Status | Clinical |
| Drug code(s) | TQH2722 |
| Brand name | None |
| mAb sequence source | mAb human |
| General Molecular Category | TBD |
| Format, general category | TBD |
| Format details | TBD |
| Isotype (Fc) | TBD |
| Light chain isotype | TBD |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | IL-4R alpha |
| Indications of clinical studies | Chronic Sinusitis With or Without Nasal Polyps, Atopic dermatitis, Phase 1 in healthy volunteers |
| Primary therapeutic area | Immune-mediated / inflammatory disorders |
| Most advanced stage of development (global) | Phase 3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | June 01, 2022 |
| Start of Phase 2 | June 15, 2023 |
| Start of Phase 3 | September 27, 2024 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. Ltd. |
| Licensee/Partner | None |
| Comments about company or candidate | NCT06552520 / CTR20242940 Phase 3 in AD started in Sep 2024. NCT06439381 Phase 2 in chronic sinusitis with or without nasal polyps due to start in June 2024. NCT06089278 Phase 2 in chronic sinusitis due to start in Nov 2023. NCT05970432 is a Phase 2 in atopic dermatitis. NCT05409326 a Phase I Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects |
| Full address of company | No. 369 South Yuzhou Rd, Haizhou District, Lianyungang, Jiangsu Province, P. R. China 222062 Asia China https://www.cttq.com/en/contact/index.htm |
TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway.
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |